With Rare Speed, Gene Editing Emerges as Biotech’s New Cutting Edge
Barron’s – Gene editing is advancing so quickly that next-generation technologies are already on the heels of Crispr-Cas9.
Read More
news
The latest
In The News
Top Life Sciences Startups to Watch in 2021
BioSpace – The NextGen Bio Class of 2021 is a stellar group of companies that are already making an enormous impact on the industry now and will continue into the future.
Read More2020 Was the Turning Point for CRISPR
Medium – Future Human – Scribe Therapeutics of Alameda, California, is using yet another form of CRISPR dubbed X-editing. Co-founded by CRISPR pioneer and Nobel winner Jennifer Doudna, PhD, the company will use the new gene-editing tool to develop treatments for neurological diseases.
Read MoreEngineering the Future of Genetic Medicine
The Scientistt Podcast – Benjamin L. Oakes is the Founder and CEO of Scribe Therapeutics, a company rewriting the story of disease and engineering the future of genetic medicine.
Read MoreDoudna’s Scribe unveils
Nature Biotechnology – Startup Scribe Therapeutics, spun out of Jennifer Doudna’s lab, emerged from stealth on 6 October with a next-generation CRISPR technology, armed with a $20-million series A round and a collaboration with Biogen.
Read More8 Biocom Member Companies Leveraging CRISPR Technology
Biocom – Another of Doudna’s spin-outs, Scribe Therapeutics, just recently announced their plans to build a platform for CRISPR-based genetic medicine to create therapies for diseases like genetically driven ALS. The company’s tools and mission have the potential to dramatically accelerate CRISPR’s applications into the clinical setting.
Read MoreInterview with Scribe Therapeutics CEO, Benjamin Oakes
CRISPR Medicine News – California-based gene-editing company Scribe Therapeutics recently unveiled its plans to develop the most advanced platform for breakthrough CRISPR-based genetic medicines.
Read MoreCRISPR-Based ALS Treatment Being Developed by Scribe and Biogen
Genetic Engineering & Biotechnology News – Best known for her pioneering work in the discovery of CRISPR, Jennifer Doudna, PhD, professor at the University of California, Berkeley, doesn’t stop or, it seems, even slow down. As of yesterday morning, Doudna can add “accept Nobel Prize” to her to-do list as she, along with Emmanuelle Charpentier, PhD, was awarded the 2020 Nobel Prize in Chemistry.
Read MoreScribe, Biogen Partner to Develop Gene Therapy for ALS, Other Neurological Diseases
ALS News Today – Founded by the scientists who originally invented CRISPR, Scribe has developed novel, custom-CRISPR tools, using a technology called X-Editing. This advanced gene-editing platform has greater editing activity and higher specificity, meaning that it can edit the target gene with greater precision than other CRISPR tools currently available.
Read MoreBiogen teams up with gene-editing startup Scribe on ALS programme
pharmaphorum – Scribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415 million deal with Biogen.
Read MoreMore Headlines
Doudna’s Scribe unveils
8 Biocom Member Companies Leveraging CRISPR Technology
Interview with Scribe Therapeutics CEO, Benjamin Oakes
CRISPR-Based ALS Treatment Being Developed by Scribe and Biogen
Scribe, Biogen Partner to Develop Gene Therapy for ALS, Other Neurological Diseases
Biogen teams up with gene-editing startup Scribe on ALS programme
Doudna Spin Out Scribe, Partners with Biogen on CRISPR-Based Treatment for ALS
Scribe Therapeutics, Biogen collaborate to develop CRISPR-based genetic medicines
Scribe Therapeutics emerges with $20M, Biogen pact to clear CRISPR hurdles
Starting with Biogen deal in ALS, Scribe planning a new chapter in CRISPR story
Press Releases
Scribe Therapeutics Co-Founder Jennifer Doudna Receives 2020 Nobel Prize in Chemistry
Honored for the development of a method for genome editing, Scribe co-founder and scientific advisor Jennifer Doudna continues to advance breakthroughs in CRISPR and genetic medicine.
Read MoreScribe Therapeutics Unveils Fully Integrated Platform for Engineering Breakthrough CRISPR-based Genetic Medicines
Scribe Therapeutics unveils fully integrated platform for engineering breakthrough CRISPR-based genetic medicines, announces Series A led by Andreessen Horowitz and collaboration with Biogen Inc. focused on development of novel genetic medicines for neurodegeneration
Read MoreScribe Therapeutics to Collaborate with Biogen to Develop CRISPR-based Genetic Medicines for Neurological Diseases, including Amyotrophic Lateral Sclerosis
Scribe Therapeutics to collaborate with Biogen to develop CRISPR-based genetic medicines for neurological diseases, including ALS
Read More